Glioblastoma remains the most aggressive adult primary brain malignancy, characterized by rapid growth and widespread central nervous system infiltration. Despite initial maximal surgical resection followed by concurrent chemoradiotherapy and adjuvant temozolomide, disease recurrence occurs in three out of four patients within one year of diagnosis. Managing disease progression is particularly challenging because standardized second-line treatment guidelines do not exist. Clinicians frequently choose between systemic therapy, re-irradiation, or repeat surgery without clear evidence comparing combined approaches. Recent real-world findings from the FROST study highlight the decisive survival benefits of recurrent glioblastoma multimodal treatment. By integrating local control interventions with systemic oncological therapy, multidisciplinary clinical teams can significantly extend overall survival and optimize patient outcomes in real-world neuro-oncology practice.

Challenges in Managing First Recurrent Glioblastoma

Therapeutic management after first glioblastoma recurrence presents formidable clinical hurdles for neuro-oncologists and neurosurgeons. Intratumoral genetic heterogeneity, therapy-resistant stem-like cell populations, and severe biological aggressiveness drive rapid relapse following standard frontline chemoradiotherapy. Consequently, tumor recurrence frequently causes severe neurological deficits, increased intracranial pressure, and progressive functional decline. Standardized salvage treatment protocols remain absent in international guidelines, leading to marked management variability across clinical centers worldwide. Furthermore, single-agent systemic therapies often provide limited progression-free survival benefits when prescribed alone. Clinicians frequently observe rapid therapeutic failure when relying exclusively on salvage chemotherapy or targeted anti-angiogenic drugs. Similarly, local salvage interventions like re-operation or stereotactic radiosurgery are often restricted to highly selected patients with focal recurrences. Therefore, single-modality strategies fail to address both focal tumor mass and microscopic infiltrative disease simultaneously. Multidisciplinary care teams urgently require robust real-world evidence to guide complex therapeutic choices for progressive high-grade gliomas.

FROST Study Design and Real-World Cohort

The FROST study evaluated real-world clinical outcomes among patients experiencing first-time glioblastoma recurrence following prior chemoradiotherapy. Researchers conducted a comprehensive multicenter observational trial including two hundred seventy-one adult patients across participating neuro-oncology centers. The study categorized patients into distinct treatment groups based on the specific salvage management modalities they received in routine practice. Specifically, one hundred ninety patients, representing seventy percent of the total cohort, received systemic treatment alone. Fifty-six patients, accounting for twenty-one percent, benefited from a multimodal approach combining systemic therapy with local interventions like surgery or radiotherapy. Twenty-five patients, or nine percent, received local therapy alone, comprising fourteen patients treated with re-irradiation and eleven treated with cytoreductive surgery. Investigators utilized Kaplan-Meier survival analysis, Cox proportional hazards regression modeling, and propensity score methods to adjust for confounding baseline characteristics. This rigorous analytical design provided highly reliable real-world evidence regarding comparative overall survival.

Comparing Outcomes: Multimodal versus Monotherapy Approaches

The FROST study demonstrated clear, statistically significant survival differences based on the selected salvage treatment strategy. Across the overall cohort of two hundred seventy-one patients, the median overall survival reached 9.9 months from first recurrence. However, patients receiving systemic treatment alone achieved a median overall survival of only 7.9 months. In sharp contrast, patients treated with local or multimodal modalities achieved a median overall survival of 12.7 months. Statistical comparison confirmed a profound survival advantage for strategies incorporating local tumor management over systemic monotherapy. Using the local or multimodal strategy as the reference baseline, Cox-stratified hazard ratio analysis revealed a hazard ratio of 2.64 for systemic treatment alone. These findings demonstrate that relying exclusively on systemic pharmaceutical agents yields markedly inferior survival compared to treatment plans that incorporate local tumor cytoreduction and control.

Survival Advantages of Recurrent Glioblastoma Multimodal Treatment

Granular subgroup analysis revealed that combining local and systemic modalities provided the greatest survival extension among all evaluated strategies. Patients receiving a comprehensive multimodal approach achieved a median overall survival of 16.2 months from first recurrence. In contrast, patients managed with local strategy alone achieved a median overall survival of only 9.3 months. Multivariate Cox regression analysis yielded a hazard ratio of 1.88 for local strategy alone compared to the multimodal reference group. Consequently, recurrent glioblastoma multimodal treatment established clear therapeutic superiority over isolated surgical or radiological interventions. Combining cytoreductive re-resection, focused stereotactic re-irradiation, and systemic oncological therapy addresses macroscopic local tumor burden while simultaneously suppressing distant microscopic infiltrative cells. This multi-targeted treatment paradigm delays intracranial progression and preserves overall functional capacity in appropriately selected patient populations.

Integrating Local and Systemic Modalities in Practice

Successfully integrating multimodal therapy into routine clinical practice requires meticulous patient selection and coordinated multidisciplinary evaluation. Neuro-oncology teams must comprehensively assess patient performance status, chronological age, time elapsed since initial radiotherapy, and updated molecular biomarker profiles. Repeat surgical resection provides immediate intracranial pressure relief, reduces macroscopic mass effect, and supplies fresh tissue for genomic sequencing to identify secondary therapeutic targets. When re-operation is anatomically unfeasible or clinically risky, stereotactic re-irradiation delivers precise, focused radiation doses while minimizing radiation necrosis in surrounding healthy brain tissue. Sequentially or concurrently administering systemic chemotherapeutic or targeted agents provides continuous suppression of microscopic infiltrative cells throughout the brain. Interdisciplinary tumor boards play an indispensable role in tailoring these combined modalities to individual patient tolerance, ensuring optimal survival gains without causing unmanageable treatment-related toxicities.

Clinical Recommendations for Multidisciplinary Care

The compelling results of the FROST study support a pivotal shift in salvage management algorithms for progressive glioblastoma. Clinical oncologists should avoid defaulting to single-agent systemic therapies when local therapeutic options remain feasible. Multidisciplinary care teams should systematically evaluate every patient presenting with first-time recurrence for candidate surgical re-resection or targeted re-irradiation prior to initiating systemic drug treatment. Combining local control measures with systemic therapy offers the highest probability of achieving extended overall survival. Furthermore, early referral to specialized tertiary neuro-oncology centers ensures timely access to advanced surgical navigation, modern stereotactic radiotherapy, and novel clinical trials. Establishing standardized, evidence-based multimodal treatment pathways across institutions can minimize practice variations and optimize long-term clinical outcomes. Adopting multimodal strategies in routine practice represents an essential advancement toward conquering recurrent glioblastoma.

Frequently Asked Questions

What is the median overall survival with multimodal therapy in recurrent glioblastoma?

In the real-world FROST study, patients with first-time recurrent glioblastoma receiving a multimodal approach achieved a median overall survival of 16.2 months. This outcome was significantly superior to local therapy alone (9.3 months) and systemic therapy alone (7.9 months), highlighting the benefit of integrated care.

Why is systemic therapy alone often insufficient for recurrent glioblastoma?

Systemic monotherapy often fails to control macroscopic recurrent tumor volume and poorly penetrates dense tumor core regions. Combining systemic agents with local interventions, such as cytoreductive re-resection or re-irradiation, effectively reduces focal mass effect while simultaneously suppressing microscopic infiltrative tumor cells throughout the brain.

How should clinicians select patients for multimodal recurrent glioblastoma treatment?

Clinicians should evaluate functional performance status, patient age, lesion location, time interval since prior radiotherapy, and molecular profiles. Multidisciplinary tumor boards analyze these factors to determine whether a patient can safely undergo repeat surgical resection or stereotactic re-irradiation combined with systemic oncological therapy.

Disclaimer: This content is for informational and educational purposes only, and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should rely on their clinical judgment and refer to the latest local and national guidelines for clinical practice.

References

1. Barbe-Richaud JB et al. From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma : FROST: multimodal treatment for GBM recurrence. J Neurooncol. 2026 Jun 23. doi: 10.1007/s11060-026-05635-y. PMID: 42334687.